Abstract Natural killer (NK) cells have emerged as a promising platform for chimeric antigen receptor (CAR) engineering, offering inherent anti-tumor activity and a favorable safety profile compared to CAR-T cells. Unlike T cells, NK cells belong to the innate immune system and do not require prior antigen sensitization, making them attractive for “off-the-shelf” allogeneic therapies. Clinical interest in CAR-NK cells has surged, with over 50 trials registered globally, driven by their reduced risk of cytokine release syndrome and graft-versus-host disease. Despite these advantages, the widespread adoption of CAR-NK therapies faces two major challenges: achieving clinically relevant NK cell numbers and ensuring post-manufacturing stability. NK cells are less abundant than T cells, exhibit limited in vitro expansion capacity, and have a short lifespan. Traditional methods rely on feeder cell co-culture, often using tumor-derived lines, which introduces technical and regulatory hurdles and yields inconsistent results. To address these limitations, we developed a feeder-free expansion protocol using human platelet lysate (hPL), enabling robust NK cell proliferation while preserving phenotype and cytotoxic function. Beyond expansion, we focused on a critical bottleneck in CAR-NK manufacturing—cryopreservation. Using proprietary cryopreservation solutions and protocols following hPL-based culture, we achieved significantly improved NK cell survival, maintenance of activating receptor expression, and retention of anti-tumor potency post-thaw. This advancement mitigates the logistical challenges of CAR-NK production, supporting scalable, ready-to-use cell therapy products. Our integrated approach—combining efficient feeder-free expansion with optimized cryopreservation—represents a major step toward reliable, high-quality CAR-NK therapies for clinical application. Citation Format: Vanesa Alonso-Camino, Andrew Sullivan. Enhanced feeder-free expansion, survival, potency and post manufacture stability of NK cells for CAR-NK therapies using human platelet lysate abstract. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 131.
Building similarity graph...
Analyzing shared references across papers
Loading...
Vanesa Alonso-Camino
Arthur K. Sullivan
Cancer Research
University of Minnesota Rochester
Building similarity graph...
Analyzing shared references across papers
Loading...
Alonso-Camino et al. (Fri,) studied this question.
www.synapsesocial.com/papers/69d1fdb0a79560c99a0a3ec2 — DOI: https://doi.org/10.1158/1538-7445.am2026-131
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: